Celldex Therapeutics is discontinuing development of barzolvolimab for moderate-to-severe atopic dermatitis (eczema) after its Phase 2 study failed to meet the primary itch endpoint or key secondary measures. The study enrolled 131 patients. At Week 16, itch scores fell 29.2% with the 300 mg dose and 16.2% with the 150 mg dose, compared with 19.5% on placebo; neither dose showed a statistically significant advantage over placebo. Measures of eczema severity and skin clearance also did not meaningfully separate from placebo, and extending treatment to Week 32 did not produce added improvement. Celldex said the results fell short of its internal threshold for continued development. The drug was well tolerated, and the company said the data suggest mast cells may contribute to eczema but are not a primary driver. The setback is specific to eczema; Celldex continues to develop barzolvolimab for chronic hives and other indications. Sources: Celldex Reports Results from Phase 2 S...
- Get link
- X
- Other Apps